SABCS 2020 | Physician adoption of NGS in the care of breast cancer patients

Andrew McKenzie and Emma Sturgill, PhD, Sarah Cannon Research Institute, Nashville, TN, discuss how next-generation sequencing (NGS) is used by clinicians in the treatment of patients with breast cancer as well as trends seen within the breast cancer genomic landscape from the implementation from these tests, including the fact that 6% of HER2-negative patients were carrying a HER2-activating mutation suggesting the potential use of HER2-targeting therapies for this patient population. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).